Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 12/20 | 0.50 |
| ▸ | CASP6 | P55212 | 3/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 6/20 | 0.44 |
| ▸ | CASP7 | P55210 | 4/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20099199 | 0.90 | CASP3 (0.50) | CASP3CASP6CASP8CASP1CASP7 | |
| SCHEMBL7745213 | 0.89 | CASP3 (0.64) | CASP3CASP6CASP8CASP1CASP7 | |
| SCHEMBL24213871 | 0.80 | CASP3 (0.56) | CASP3CASP6CASP8CASP1CASP7 | |
| SCHEMBL17494194 | 0.80 | CASP3 (0.56) | CASP3CASP6CASP8CASP1CASP7 | |
| SCHEMBL14646635 | 0.80 | CASP3 (0.56) | CASP3CASP6CASP8CASP1CASP7 | |
| Naphthalene SCHEMBL7418235 | 0.78 | CASP1 (0.55) | CASP3CASP1 | |
| SCHEMBL14070409 | 0.77 | CASP3 (0.56) | CASP3CASP8CASP1CASP7CASP9 | |
| SCHEMBL7472606 | 0.76 | CASP3 (0.56) | CASP3CASP8CASP1CASP7CASP9 | |
| SCHEMBL614741 | 0.76 | CASP3 (0.62) | CASP3CASP6CASP8CASP1CASP7 | |
| SCHEMBL29384302 | 0.76 | CASP3 (0.60) | CASP3CASP6CASP8CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9352010-B2 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP3 18/4885CASP6 22/4885CASP8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.